• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 SARS-CoV-2 变异株 B.1.1.7、B.1.351 和 B.1.1.28.1 的结构-功能分析:临床、诊断、治疗和公共卫生影响。

Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.

机构信息

JH-Institute of Molecular Medicine, Jamia Hamdard, New Delhi 110062, India.

ICMR National Institute of Pathology, Safdarjung Hospital Campus, New Delhi 110029, India.

出版信息

Viruses. 2021 Mar 9;13(3):439. doi: 10.3390/v13030439.

DOI:10.3390/v13030439
PMID:33803400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8000172/
Abstract

SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2) has accumulated multiple mutations during its global circulation. Recently, three SARS-CoV-2 lineages, B.1.1.7 (501Y.V1), B.1.351 (501Y.V2) and B.1.1.28.1 (P.1), have emerged in the United Kingdom, South Africa and Brazil, respectively. Here, we have presented global viewpoint on implications of emerging SARS-CoV-2 variants based on structural-function impact of crucial mutations occurring in its spike (S), ORF8 and nucleocapsid (N) proteins. While the N501Y mutation was observed in all three lineages, the 501Y.V1 and P.1 accumulated a different set of mutations in the S protein. The missense mutational effects were predicted through a COVID-19 dedicated resource followed by atomistic molecular dynamics simulations. Current findings indicate that some mutations in the S protein might lead to higher affinity with host receptors and resistance against antibodies, but not all are due to different antibody binding (epitope) regions. Mutations may, however, result in diagnostic tests failures and possible interference with binding of newly identified anti-viral candidates against SARS-CoV-2, likely necessitating roll out of recurring "flu-like shots" annually for tackling COVID-19. The functional relevance of these mutations has been described in terms of modulation of host tropism, antibody resistance, diagnostic sensitivity and therapeutic candidates. Besides global economic losses, post-vaccine reinfections with emerging variants can have significant clinical, therapeutic and public health impacts.

摘要

SARS-CoV-2(严重急性呼吸系统综合症冠状病毒 2)在其全球传播过程中积累了多种突变。最近,三种 SARS-CoV-2 谱系,B.1.1.7(501Y.V1)、B.1.351(501Y.V2)和 B.1.1.28.1(P.1),分别在英国、南非和巴西出现。在这里,我们根据其刺突(S)、ORF8 和核衣壳(N)蛋白中发生的关键突变的结构-功能影响,从全球角度介绍了新兴 SARS-CoV-2 变体的意义。虽然在所有三个谱系中都观察到了 N501Y 突变,但 501Y.V1 和 P.1 在 S 蛋白中积累了一组不同的突变。通过专门用于 COVID-19 的资源进行预测,随后进行原子分子动力学模拟,预测错义突变的效应。目前的研究结果表明,S 蛋白中的一些突变可能导致与宿主受体的更高亲和力和对抗体的抗性,但并非所有突变都是由于不同的抗体结合(表位)区域。然而,突变可能导致诊断测试失败,并可能干扰对 SARS-CoV-2 的新鉴定抗病毒候选药物的结合,可能需要每年推出新的“流感样疫苗”来应对 COVID-19。这些突变的功能相关性已根据宿主嗜性、抗体耐药性、诊断敏感性和治疗候选物的调节来描述。除了全球经济损失外,新兴变体的疫苗接种后再感染可能会对临床、治疗和公共卫生产生重大影响。

相似文献

1
Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.新型 SARS-CoV-2 变异株 B.1.1.7、B.1.351 和 B.1.1.28.1 的结构-功能分析:临床、诊断、治疗和公共卫生影响。
Viruses. 2021 Mar 9;13(3):439. doi: 10.3390/v13030439.
2
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?新型冠状病毒(SARS-CoV-2)刺突蛋白的突变会导致新冠疫苗失效吗?
J Korean Med Sci. 2021 May 10;36(18):e124. doi: 10.3346/jkms.2021.36.e124.
3
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.新型 SARS-CoV-2 变异株的进化、传播模式和突变特征。
mBio. 2021 Aug 31;12(4):e0114021. doi: 10.1128/mBio.01140-21.
4
Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines.SARS-CoV-2 新兴显著刺突蛋白突变的动力学预测表明需要更新疫苗。
Biochimie. 2021 Dec;191:91-103. doi: 10.1016/j.biochi.2021.08.011. Epub 2021 Sep 8.
5
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
6
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
7
Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.基因组监测揭示了在巴西对 SARS-CoV-2 B.1.351(贝塔)变体(20H/501Y.V2)的早期检测。
J Med Virol. 2021 Dec;93(12):6782-6787. doi: 10.1002/jmv.27190. Epub 2021 Jul 19.
8
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
9
A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.针对弗林蛋白酶的可行替代策略可破坏 SARS-CoV-2 感染周期。
Microbiol Spectr. 2022 Feb 23;10(1):e0236421. doi: 10.1128/spectrum.02364-21. Epub 2022 Feb 9.
10
Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.抗 SARS-CoV-2 疫苗和单克隆抗体应对病毒变异。
Viruses. 2021 Jun 18;13(6):1171. doi: 10.3390/v13061171.

引用本文的文献

1
Multiplex RT-qPCR strategy for SARS-CoV-2 variants detection in developing countries without ngs: The Bolivian experience.在没有二代测序技术的发展中国家检测新型冠状病毒变异株的多重逆转录定量聚合酶链反应策略:玻利维亚的经验
Epidemiol Infect. 2025 Aug 15;153:e94. doi: 10.1017/S095026882510037X.
2
Impact of African-Specific ACE2 Polymorphisms on Omicron BA.4/5 RBD Binding and Allosteric Communication Within the ACE2-RBD Protein Complex.非洲特异性ACE2多态性对奥密克戎BA.4/5刺突蛋白受体结合域(RBD)与ACE2-RBD蛋白复合物内变构通讯的影响。
Int J Mol Sci. 2025 Feb 6;26(3):1367. doi: 10.3390/ijms26031367.
3
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins.

本文引用的文献

1
Clinical, Laboratory, and Radiologic Characteristics of Patients With Initial False-Negative Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Amplification Test Results.初始严重急性呼吸综合征冠状病毒2核酸扩增检测结果为假阴性患者的临床、实验室及影像学特征
Open Forum Infect Dis. 2020 Nov 24;8(1):ofaa559. doi: 10.1093/ofid/ofaa559. eCollection 2021 Jan.
2
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
3
靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关键蛋白的共价抑制剂的结构基础研究进展
Curr Med Chem. 2025;32(19):3790-3824. doi: 10.2174/0109298673323348241208080419.
4
Computational screening combined with well-tempered metadynamics simulations identifies potential TMPRSS2 inhibitors.计算筛选与调谐平均分子动力学模拟相结合,鉴定潜在的 TMPRSS2 抑制剂。
Sci Rep. 2024 Jul 13;14(1):16197. doi: 10.1038/s41598-024-65296-7.
5
Progressive Evolutionary Dynamics of Gene-Specific ω Led to the Emergence of Novel SARS-CoV-2 Strains Having Super-Infectivity and Virulence with Vaccine Neutralization.基因特异性ω的渐进进化动力学导致具有超级感染力和毒力的新型 SARS-CoV-2 菌株的出现,这些菌株具有疫苗中和作用。
Int J Mol Sci. 2024 Jun 7;25(12):6306. doi: 10.3390/ijms25126306.
6
A Comparative Analysis of Innate Immune Responses and the Structural Characterization of Spike from SARS-CoV-2 Gamma Variants and Subvariants.新冠病毒伽马变异株及其亚变异株天然免疫反应的比较分析与刺突蛋白的结构表征
Microorganisms. 2024 Apr 2;12(4):720. doi: 10.3390/microorganisms12040720.
7
Air transportation as a puzzle piece of COVID-19 in Africa?航空运输是非洲新冠疫情拼图的一块?
Res Transp Bus Manag. 2022 Jun;43:100780. doi: 10.1016/j.rtbm.2022.100780. Epub 2022 Jan 10.
8
Peptide Variant Detection by a Living Yeast Biosensor via an Epitope-Selective Protease.通过表位选择性蛋白酶利用活酵母生物传感器检测肽变体
Biodes Res. 2023 Mar 15;5:0003. doi: 10.34133/bdr.0003. eCollection 2023.
9
The rates and symptoms of natural and breakthrough infection pre- and post- Covid-19 non-mRNA vaccination at various peaks amongst Iranian healthcare workers.伊朗医护人员在新冠病毒非 mRNA 疫苗接种前后各个高峰期自然感染和突破性感染的发生率和症状。
Virol J. 2023 Aug 18;20(1):182. doi: 10.1186/s12985-023-02156-2.
10
Polypharmacology guided drug repositioning approach for SARS-CoV2.多靶标药物重定位策略用于治疗 SARS-CoV-2。
PLoS One. 2023 Aug 9;18(8):e0289890. doi: 10.1371/journal.pone.0289890. eCollection 2023.
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
4
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
5
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.循环 Sars-CoV-2 刺突 N439K 变体在保持适应性的同时逃避抗体介导的免疫。
Cell. 2021 Mar 4;184(5):1171-1187.e20. doi: 10.1016/j.cell.2021.01.037. Epub 2021 Jan 28.
6
CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants.CovMT:一个交互式的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突变追踪器,重点关注关键变异株。
Lancet Infect Dis. 2021 May;21(5):602. doi: 10.1016/S1473-3099(21)00078-5. Epub 2021 Feb 8.
7
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.BNT162b2 疫苗诱导的血清对 SARS-CoV-2 刺突 69/70 缺失、E484K 和 N501Y 变异株的中和作用。
Nat Med. 2021 Apr;27(4):620-621. doi: 10.1038/s41591-021-01270-4. Epub 2021 Feb 8.
8
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.尽管血清阳性率很高,巴西玛瑙斯仍出现新冠病毒的卷土重来。
Lancet. 2021 Feb 6;397(10273):452-455. doi: 10.1016/S0140-6736(21)00183-5. Epub 2021 Jan 27.
9
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.预测用于治疗 COVID-19 的抗体所识别的病毒突变逃逸情况。
Science. 2021 Feb 19;371(6531):850-854. doi: 10.1126/science.abf9302. Epub 2021 Jan 25.
10
Covid-19: What new variants are emerging and how are they being investigated?新冠疫情:正在出现哪些新变种,它们是如何被研究的?
BMJ. 2021 Jan 18;372:n158. doi: 10.1136/bmj.n158.